Kinetic Medicaments (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 20-06-2024
- Paid Up Capital ₹ 1.00 M
as on 20-06-2024
- Company Age 16 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 2.21%
(FY 2022)
- Profit 76.89%
(FY 2022)
- Ebitda -639.07%
(FY 2022)
- Net Worth -2.15%
(FY 2022)
- Total Assets 14.01%
(FY 2022)
About Kinetic Medicaments (India)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Manoj Darak and Neha Darak serve as directors at the Company.
- CIN/LLPIN
U24239MH2008PTC184577
- Company No.
184577
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jul 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kinetic Medicaments (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Darak  | Managing Director | 11-Jul-2008 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Neha Darak | Director | 24-Apr-2019 | Current |
Financial Performance of Kinetic Medicaments (India).
Kinetic Medicaments (India) Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 2.21% increase. The company also saw a substantial improvement in profitability, with a 76.89% increase in profit. The company's net worth dipped by a decrease of 2.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kinetic Medicaments (India)?
In 2020, Kinetic Medicaments (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Kchanakya Net Study Private LimitedActive 3 years 11 months
Manoj Darak and Neha Darak are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kinetic Medicaments (India)?
Kinetic Medicaments (India) has a workforce of 9 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kinetic Medicaments (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kinetic Medicaments (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
